<i>NTRK</i> Fusion–Positive Thyroid Carcinoma: From Diagnosis to Targeted Therapy

<i>NTRK1</i>/<i>3</i> fusions are seen in PTC, PDTC, and ATC, and a follicular growth pattern was observed in a high proportion of cases. In patients treated with larotrectinib, <i>NTRK</i> solvent front mutations are the main resistance mechanism, frequently occurring in PDTC/ATC. Responses to single-agent TRK inhibitor are short-lived in patients with ATC; thus, these drugs should be used with caution in this population.

Authors

Institutions

Publication Details

Journal
JCO Precision Oncology
Published
2025-02-21
DOI
https://doi.org/10.1200/po.24.00321
Citations
6
Primary Topic
Thyroid Cancer Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
7.77
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

NTRK Fusion–Positive Thyroid Carcinoma: From Diagnosis to Targeted Therapy

Sarah Hamidi, Priyanka Chandrasekhar Iyer, Keyur P. Patel, Mark Zafereo et al.
6 citations
JCO Precision Oncology
Thyroid Cancer Diagnosis and Treatment
7.77
article

NTRK Fusion–Positive Thyroid Carcinoma: From Diagnosis to Targeted Therapy

Sarah Hamidi, Priyanka Chandrasekhar Iyer, Keyur P. Patel, Mark Zafereo, Sinchita Roy‐Chowdhuri, David S. Hong, Sasan Fazeli, Vicente Rodrigues Marczyk, Steven Gerard Waguespack, Mark J. Routbort, Naifa Lamki Busaidy, Jennifer Wang, Anastasios Maniakas, Michelle D. Williams, Rajyalakshmi Luthra, S. Mohsen Hosseini, Ramona Dadu, Mimi I-Nan Hu, Steven I. Sherman, Maria E. Cabanillas, Salmaan Ahmed, F. Anthony San Lucas
article en
6 citations

Abstract

<i>NTRK1</i>/<i>3</i> fusions are seen in PTC, PDTC, and ATC, and a follicular growth pattern was observed in a high proportion of cases. In patients treated with larotrectinib, <i>NTRK</i> solvent front mutations are the main resistance mechanism, frequently occurring in PDTC/ATC. Responses to single-agent TRK inhibitor are short-lived in patients with ATC; thus, these drugs should be used with caution in this population.

JCO Precision OncologyVol. 9(9)
The University of Texas MD Anderson Cancer Center (US)
Good health and well-being
Openalex Percentile: Top 3%
Thyroid Cancer Diagnosis and Treatment
7.77
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.